Fig. 3: COVID-compatible symptoms of survey participants.
From: SARS-CoV-2 antibody seroprevalence and associated risk factors in an urban district in Cameroon
Participants reported any COVID-compatible acute symptoms (all shown in panel c), which were experienced between March 1, 2020 and the date of survey. a Matrix plot showing the intersection of symptomaticity with IgG seropositivity. The area of each rectangle is proportional to the number of respondents in the category. b The ten most common symptom profiles among IgG seropositive individuals. c Comparison in frequency of symptoms between IgG seropositive and seronegative individuals. χ-square p-values are shown for significant differences between seropositive and seronegative symptomatic proportions.
